Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
CONCLUSION: This nationwide study showed that standard chemotherapy with low-dose anthracycline is a risk factor for late-onset CHF in breast cancer survivors who were in their 50 s at breast cancer diagnosis. Long-term monitoring of late CHF should be considered in these younger breast cancer survivors.
PMID: 32771950 [PubMed - as supplied by publisher]
Source: Breast - Category: Cancer & Oncology Authors: Chung IY, Lee JW, Moon HG, Shin KH, Han W, Son BH, Ahn SH, Noh DY Tags: Breast Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Congestive Heart Failure | Heart | Heart Failure | Insurance | Study